| Managing the toxicities of CAR T-cell therapy |
35 |
| CAR T-cell therapy: Full speed ahead |
19 |
| Multiple myeloma: Every year a new standard? |
16 |
| The use of droplet digital PCR in liquid biopsies: A highly sensitive technique for MYD88 p.(L265P) detection in cerebrospinal fluid |
16 |
| Arterial occlusive events in chronic myeloid leukemia patients treated with ponatinib in the real-life practice are predicted by the Systematic Coronary Risk Evaluation (SCORE) chart |
16 |
| Epidemiology, outcome, and risk factors for infectious complications in myelofibrosis patients receiving ruxolitinib: A multicenter study on 446 patients |
13 |
| Management of adverse events associated with idelalisib treatment in chronic lymphocytic leukemia and follicular lymphoma: A multidisciplinary position paper |
12 |
| Practical management of ibrutinib in the real life: Focus on atrial fibrillation and bleeding |
12 |
| Cutaneous lymphomas-An update 2019 |
11 |
| Prognostic role of baseline F-18-FDG PET/CT parameters in MALT lymphoma |
11 |
| Circulating exosomal long noncoding RNA PRINS-First findings in monoclonal gammopathies |
9 |
| Primary central nervous system lymphoma: A curable disease |
8 |
| The modern approach to mantle cell lymphoma |
8 |
| Rituximab in primary central nervous system lymphoma-A systematic review and meta-analysis |
8 |
| Daratumumab for relapsed or refractory AL amyloidosis with high plasma cell burden |
8 |
| The impacts of zanubrutinib on immune cells in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma |
8 |
| LncRNA LINP1 regulates acute myeloid leukemia progression via HNF4 alpha/AMPK/WNT5A signaling pathway |
7 |
| Long-term results of the risk-stratified treatment of childhood acute lymphoblastic leukemia in China |
7 |
| Evidence of long-lasting anti-CD19 activity of engrafted CD19 chimeric antigen receptor-modified T cells in a phase I study targeting pediatrics with acute lymphoblastic leukemia |
7 |
| Spectrum and immunophenotyping of 653 patients with B-cell chronic lymphoproliferative disorders in China: A single-centre analysis |
6 |
| Breast implant-associated anaplastic large cell lymphoma and other rare T-cell lymphomas |
6 |
| Treating Hodgkin lymphoma in the new millennium: Relapsed and refractory disease |
6 |
| MicroRNA expression profiles discriminate childhood T- from B-acute lymphoblastic leukemia |
6 |
| Delayed methotrexate elimination: Incidence, interaction with antacid drugs, and clinical consequences? |
6 |
| Cytomegalovirus infection in hematologic malignancy settings other than the allogeneic transplant |
6 |
| The lenalidomide/bortezomib/dexamethasone regimen for the treatment of blastic plasmacytoid dendritic cell neoplasm |
6 |
| Efficacy and safety of ruxolitinib in intermediate-1 IPSS risk myelofibrosis patients: Results from an independent study |
6 |
| The use of BRAF V600E mutation-specific immunohistochemistry in pediatric Langerhans cell histiocytosis |
6 |
| Rheumatoid arthritis and lymphoma: Incidence, pathogenesis, biology, and outcome |
6 |
| Lymphomas associated with chronic hepatitis C virus infection: A prospective multicenter cohort study from the Rete Ematologica Lombarda (REL) clinical network |
6 |
| CD200 included in a 4-marker modified Matutes score provides optimal sensitivity and specificity for the diagnosis of chronic lymphocytic leukaemia |
5 |
| Frontline treatment of diffuse large B-cell lymphoma: Beyond R-CHOP |
5 |
| Optimizing venetoclax dose in combination with low intensive therapies in elderly patients with newly diagnosed acute myeloid leukemia: An exposure-response analysis |
5 |
| Plasma soluble programmed death ligand 1 levels predict clinical response in peripheral T-cell lymphomas |
5 |
| Cardiovascular mortality among patients with non-Hodgkin lymphoma: Differences according to lymphoma subtype |
5 |
| Serum albumin or body mass index: Which prognostic factor for survival in patients with acute myeloblastic leukaemia? |
5 |
| Tocilizumab for severe cytokine-release syndrome after haploidentical donor transplantation in a patient with refractory Epstein-Barr virus-positive diffuse large B-cell lymphoma |
5 |
| Severe pneumonia associated with ibrutinib monotherapy for CLL and lymphoma |
5 |
| A pilot phase II study of ofatumumab monotherapy for extranodal marginal zone B-cell lymphoma of the mucosa-associated lymphoid tissue (MALT) lymphoma |
5 |
| Epstein-Barr virus lytic cycle involvement in diffuse large B cell lymphoma |
5 |
| Comparison between thrombotic risk scores in essential thrombocythemia and survival implications |
5 |
| Non-Hodgkin lymphoma in South East Asia: An analysis of the histopathology, clinical features, and survival from Thailand |
4 |
| Relationship between response rates and median progression-free survival in non-Hodgkin's lymphoma: A meta-analysis of published clinical trials |
4 |
| Response and survival benefit with chemoimmunotherapy in Epstein-Barr virus-positive diffuse large B-cell lymphoma |
4 |
| Nonpegylated liposomal doxorubicin combination regimen in patients with diffuse large B-cell lymphoma and cardiac comorbidity. Results of the HEART01 phase II trial conducted by the Fondazione Italiana Linfomi |
4 |
| Outcome of patients older than 80years with diffuse large B-cell lymphoma (DLBCL) treated with standard immunochemotherapy: A large retrospective study from 4 institutions |
4 |
| New treatment options in hairy cell leukemia with focus on BRAF inhibitors |
4 |
| The role of maintenance therapy in patients with diffuse large B cell lymphoma: A systematic review and meta-analysis |
4 |
| Treatment of mucosa associated lymphoid tissue lymphoma with a long-term once-weekly regimen of oral azithromycin: Results from the phase II MALT-A trial |
4 |
| Long noncoding RNAs and their epigenetic function in hematological diseases |
4 |
